Actimed Therapeutics

We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, to prolong and improve their quality of life, restore their dignity and ease the burden for the patient, carer, and provider.

Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there are few treatment options and no globally approved pharmaceutical product for the treatment or prevention of cancer-related cachexia.

Our approach focuses on a class of agents that may have multiple effects on the fundamental biology of cachexia to reduce catabolism (weight loss), increase and maintain anabolism (weight gain, particularly muscle mass gain), decrease fatigue, and improve appetite.

Our lead product, S-pindolol benzoate (ACM-001.1) is a new salt of S-pindolol in clinical development for cancer-related cachexia. S-pindolol has demonstrated promising results in a Phase 2a, proof of concept trial. A Phase 2b/3 clinical development programme for S-pindolol benzoate (ACM-001.1), the IMPACT Programme, is planned (Improving cancer cachexia with ACTAs in NSCLC/CRC).

Actimed received FDA approval of its Investigational New Drug (IND) application for the IMPACT Programme in August 2023. The Company plans to dose the first patients in 2025.

Our vision is to develop the first globally approved treatment for cancer cachexia and to develop a product portfolio to bring much needed innovation to the treatment of cachexia, amyotrophic lateral sclerosis and other muscle wasting conditions.

Two of our founders, Professor Andrew Coats and Professor Stefan Anker, are world-leading physicians in cachexia research. Actimed is led by a management team and board with significant global experience in the development of new therapeutics across multiple indications.